Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fasten Onco Digital Therapy in Early-Stage Triple-Negative Breast Cancer
NCT07884721Not yet recruiting
- Sponsor
- FASTEN
- Start
- Oct 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Randomised, open-label trial in triple-negative breast cancer (TNBC) (2 arms), sponsored by FASTEN. Primary endpoint: Change From Baseline in FACIT-Fatigue Total Score. Planned start Oct 2026; status: not yet recruiting.
02
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT07884721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07884721.